Pharmacological Evaluation of the Efficacy of Dysoxylum Binectariferum Stem Bark and Its Active Constituent Rohitukine in Regulation of Dyslipidemia in Rats

Overview

Journal J Nat Med

Publisher Springer

Date 2014 Mar 29

PMID 24677095

Citations 2

Authors

Sunil K Mishra

Shashi Tiwari

Shishir Shrivastava

Ravi Sonkar

Vaibhav Mishra

Sunil K Nigam

Anil K Saxena

Gitika Bhatia

Snober S Mir

Affiliations

Soon will be listed here.

Abstract

The antidyslipidemic effect of the ethanolic extract of Dysoxylum binectariferum stem bark and its major active constituent rohitukine was evaluated in a high fat diet (HFD)-fed dyslipidemic rat model. Chronic feeding of ethanolic extract (200 mg/kg) in HFD-fed rats showed significant lipid lowering activity. The bioassay guided fractionation of ethanolic extract resulted in the identification of known alkaloid rohitukine as major active constituent. Rohitukine (50 mg/kg) significantly decreased the plasma levels of total cholesterol (24 %), phospholipids (25 %), triglycerides (27 %), very low density lipoprotein (27 %) and low density lipoprotein (32 %) accompanied with an increase in high density lipoprotein (21 %). The present study demonstrated that ethanolic extract of Dysoxylum binectariferum stem bark and its major constituent rohitukine both have antidyslipidemic as well as antioxidant potentials. The antidyslipidemic activity of rohitukine can be correlated to its effect on enzymes involved in lipid metabolism.

Citing Articles

A wound inducible chalcone synthase gene from () regulates flavonoid biosynthesis.

Mahajan V, Chouhan R, Jamwal V, Kapoor N, Gandhi S Physiol Mol Biol Plants. 2023; 29(7):959-969.

PMID: 37649885 PMC: 10462589. DOI: 10.1007/s12298-023-01344-2.

Exogenously Applied Rohitukine Inhibits Photosynthetic Processes, Growth and Induces Antioxidant Defense System in .

Ahmed S, Asgher M, Kumar A, Gandhi S Antioxidants (Basel). 2022; 11(8).

PMID: 36009231 PMC: 9404761. DOI: 10.3390/antiox11081512.

References

Jain K, Kathiravan M, Somani R, Shishoo C . The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007; 15(14):4674-99. DOI: 10.1016/j.bmc.2007.04.031. View

Sashidhara K, Singh S, Srivastava A, Puri A, Chhonker Y, Bhatta R . Discovery of a new class of HMG-CoA reductase inhibitor from Polyalthia longifolia as potential lipid lowering agent. Eur J Med Chem. 2011; 46(10):5206-11. DOI: 10.1016/j.ejmech.2011.08.012. View

ZILVERSMIT D, Davis A . Microdetermination of plasma phospholipids by trichloroacetic acid precipitation. J Lab Clin Med. 1950; 35(1):155-60. View

Nagasaki T, Akanuma Y . A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity. Clin Chim Acta. 1977; 75(3):371-5. DOI: 10.1016/0009-8981(77)90355-2. View

Rader D, FitzGerald G . State of the art: atherosclerosis in a limited edition. Nat Med. 1998; 4(8):899-900. DOI: 10.1038/nm0898-899. View

Sprecher D . Triglycerides as a risk factor for coronary artery disease. Am J Cardiol. 1999; 82(12A):49U-56U; discussion 85U-86U. DOI: 10.1016/s0002-9149(98)00953-9. View

Khanna A, Rizvi F, Chander R . Lipid lowering activity of Phyllanthus niruri in hyperlipemic rats. J Ethnopharmacol. 2002; 82(1):19-22. DOI: 10.1016/s0378-8741(02)00136-8. View

Mahboob M, Rahman M, Grover P . Serum lipid peroxidation and antioxidant enzyme levels in male and female diabetic patients. Singapore Med J. 2005; 46(7):322-4. View

Parthasarathy S, Steinberg D, Witztum J . The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med. 1992; 43:219-25. DOI: 10.1146/annurev.me.43.020192.001251. View

10.

MOSBACH E, KALINSKY H, Halpern E, KENDALL F . Determination of deoxycholic and cholic acids in bile. Arch Biochem Biophys. 1954; 51(2):402-10. DOI: 10.1016/0003-9861(54)90495-6. View

11.

Sparrow C, Olszewski J . Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions. J Lipid Res. 1993; 34(7):1219-28. View

12.

Istvan E, Deisenhofer J . Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001; 292(5519):1160-4. DOI: 10.1126/science.1059344. View

13.

Prasad J, Shrivastava A, Khanna A, Bhatia G, Awasthi S, Narender T . Antidyslipidemic and antioxidant activity of the constituents isolated from the leaves of Calophyllum inophyllum. Phytomedicine. 2012; 19(14):1245-9. DOI: 10.1016/j.phymed.2012.09.001. View

14.

Drechsler M, Megens R, van Zandvoort M, Weber C, Soehnlein O . Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 2010; 122(18):1837-45. DOI: 10.1161/CIRCULATIONAHA.110.961714. View

15.

Eisenberg D . Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med. 1998; 104(2A):2S-5S. DOI: 10.1016/s0002-9343(98)00038-2. View

16.

Singh N, Singh P, Shrivastva S, Mishra S, Lakshmi V, Sharma R . Gastroprotective effect of anti-cancer compound rohitukine: possible role of gastrin antagonism and H(+) K (+)-ATPase inhibition. Naunyn Schmiedebergs Arch Pharmacol. 2011; 385(3):277-86. DOI: 10.1007/s00210-011-0711-1. View

17.

Mayes P, Felts J . The functional status of lipoprotein lipase in rat liver. Biochem J. 1968; 108(3):483-7. PMC: 1198834. DOI: 10.1042/bj1080483. View

18.

Senderowicz A, Headlee D, Stinson S, Lush R, Kalil N, Villalba L . Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998; 16(9):2986-99. DOI: 10.1200/JCO.1998.16.9.2986. View

19.

Mohanakumara P, Sreejayan N, Priti V, Ramesha B, Ravikanth G, Ganeshaiah K . Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine. Fitoterapia. 2009; 81(2):145-8. DOI: 10.1016/j.fitote.2009.08.010. View

20.

BUCOLO G, David H . Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973; 19(5):476-82. View